All patients
Age < 65y (younger) Age > 75y (older) Asian type BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male RAS mutant RAS wild type
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mCRC - 1st line (L1), pembrolizumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias progression or deaths (PFS)detailed results KEYNOTE-177, 2020 0.60 [0.45; 0.80]
0.60 [0.45 ; 0.80 ] KEYNOTE-177, 2020 1 0% 307 NA not evaluable objective responses (ORR)detailed results KEYNOTE-177, 2020 1.57 [0.99; 2.50]
1.57 [0.99 ; 2.50 ] KEYNOTE-177, 2020 1 0% 307 NA not evaluable AE (any grade)detailed results KEYNOTE-177, 2020 0.26 [0.03; 2.38]
0.26 [0.03 ; 2.38 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.41 [0.25; 0.67]
0.41 [0.25 ; 0.67 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-177, 2020 0.79 [0.26; 2.42]
0.79 [0.26 ; 2.42 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.14 [0.08; 0.23]
0.14 [0.08 ; 0.23 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-177, 2020 0.47 [0.02; 13.99]
0.47 [0.02 ; 13.99 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 3.77 [0.17; 84.42]
3.77 [0.17 ; 84.42 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.26 [0.05; 1.26]
0.26 [0.05 ; 1.26 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.09 [0.00; 1.67]
0.09 [0.00 ; 1.67 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 9.63 [0.52; 177.85]
9.63 [0.52 ; 177.85 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.15 [0.01; 3.08]
0.15 [0.01 ; 3.08 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 1.88 [0.06; 56.32]
1.88 [0.06 ; 56.32 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.18 [0.05; 0.66]
0.18 [0.05 ; 0.66 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Dizziness TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Epistaxis TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.20 [0.06; 0.72]
0.20 [0.06 ; 0.72 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 7.65 [0.40; 146.03]
7.65 [0.40 ; 146.03 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 1.88 [0.17; 20.97]
1.88 [0.17 ; 20.97 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 2.84 [0.29; 27.62]
2.84 [0.29 ; 27.62 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.47 [0.02; 13.99]
0.47 [0.02 ; 13.99 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.07 [0.00; 1.35]
0.07 [0.00 ; 1.35 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.47 [0.02; 13.99]
0.47 [0.02 ; 13.99 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.15 [0.01; 3.08]
0.15 [0.01 ; 3.08 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.02 [0.00; 0.30]
0.02 [0.00 ; 0.30 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.47 [0.02; 13.99]
0.47 [0.02 ; 13.99 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 1.88 [0.06; 56.32]
1.88 [0.06 ; 56.32 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.47 [0.02; 13.99]
0.47 [0.02 ; 13.99 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.15 [0.01; 3.08]
0.15 [0.01 ; 3.08 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.47 [0.02; 13.99]
0.47 [0.02 ; 13.99 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.06; 15.08]
0.93 [0.06 ; 15.08 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.13; 6.72]
0.93 [0.13 ; 6.72 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.07 [0.00; 1.35]
0.07 [0.00 ; 1.35 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-177, 2020 0.09 [0.00; 1.67]
0.09 [0.00 ; 1.67 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Abdominal pain AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.34; 2.55]
0.93 [0.34 ; 2.55 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Alopecia AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.47 [0.19; 1.15]
0.47 [0.19 ; 1.15 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-177, 2020 1.88 [0.06; 56.32]
1.88 [0.06 ; 56.32 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.46 [0.11; 1.86]
0.46 [0.11 ; 1.86 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-177, 2020 1.88 [0.17; 20.97]
1.88 [0.17 ; 20.97 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.06 [0.00; 1.13]
0.06 [0.00 ; 1.13 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.50 [0.21; 1.16]
0.50 [0.21 ; 1.16 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Dizziness AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Dry skin AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Dyspepsia AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-177, 2020 1.88 [0.06; 56.32]
1.88 [0.06 ; 56.32 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Epistaxis AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.41 [0.15; 1.10]
0.41 [0.15 ; 1.10 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Headache AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Hypertension AE (grade 3-4)detailed results KEYNOTE-177, 2020 1.51 [0.57; 4.00]
1.51 [0.57 ; 4.00 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.02; 47.41]
0.93 [0.02 ; 47.41 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-177, 2020 1.25 [0.28; 5.70]
1.25 [0.28 ; 5.70 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Increased ALT AE (grade 3-4)detailed results KEYNOTE-177, 2020 1.25 [0.28; 5.70]
1.25 [0.28 ; 5.70 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.47 [0.02; 13.99]
0.47 [0.02 ; 13.99 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.61 [0.17; 2.22]
0.61 [0.17 ; 2.22 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Neutropenia AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.02 [0.00; 0.30]
0.02 [0.00 ; 0.30 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.47 [0.02; 13.99]
0.47 [0.02 ; 13.99 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.47 [0.02; 13.99]
0.47 [0.02 ; 13.99 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.23 [0.01; 5.17]
0.23 [0.01 ; 5.17 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.15 [0.01; 3.08]
0.15 [0.01 ; 3.08 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Pruritus AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.47 [0.02; 13.99]
0.47 [0.02 ; 13.99 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Pyrexia AE (grade 3-4)detailed results KEYNOTE-177, 2020 1.88 [0.06; 56.32]
1.88 [0.06 ; 56.32 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.06; 15.08]
0.93 [0.06 ; 15.08 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Stomatitis AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.07 [0.00; 1.35]
0.07 [0.00 ; 1.35 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.26 [0.05; 1.26]
0.26 [0.05 ; 1.26 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable Weight decreased AE (grade 3-4)detailed results KEYNOTE-177, 2020 0.93 [0.06; 15.08]
0.93 [0.06 ; 15.08 ] KEYNOTE-177, 2020 1 0% 296 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-01 08:28 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 137
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561